Home・Aktien・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Geschlossen

12.89 -0.31

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

12.85

Max

12.98

Schlüsselkennzahlen
By Trading Economics
Einkommen	-4.3M -18M
EPS	-0.19
Angestellte	37
EBITDA	-5.3M -17M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+128.51% upside

Dividenden
By Acuity
Nächstes Ergebnis	3. Nov. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	86M 1.2B
Vorheriger Eröffnungskurs	13.2
Vorheriger Schlusskurs	12.89

Corvus Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

12. Sept. 2026, 23:51 UTC

China's House Price Index YoY release on September 15 expected to show continued decline amid cautious market sentiment and rising global oil prices.

12. Sept. 2026, 23:41 UTC

Philadelphia Fed Manufacturing Index Set for Release Amid Heightened Market Sensitivity to Inflation and Interest Rate Hike Expectations.

12. Sept. 2026, 23:41 UTC

U.S. Building Permits Expected to Reach 1.41 Million for August Amid Mixed Housing Sentiment Ahead of September Release

12. Sept. 2026, 23:41 UTC

Housing Starts Data Release on September 17, 2026, Expected to Show Continued Caution Amid High Mortgage Rates and Recent Declines.

12. Sept. 2026, 23:41 UTC

Upcoming U.S. Building Permits Report on September 17, 2026, Expected to Reflect Economic Health Amid Stable Market Sentiment.

12. Sept. 2026, 23:41 UTC

Upcoming Housing Starts Data Release Amid Rising Mortgage Rates Raises Concerns for U.S. Construction Market

12. Sept. 2026, 23:21 UTC

U.S. Retail Sales Ex Autos Expected to Rise 0.5% in August Amid Mixed Economic Sentiment and Inflation Concerns

12. Sept. 2026, 23:21 UTC

U.S. Import Prices Expected to Rise 0.2% Amid Inflation Concerns and Fed Rate Speculation Following Geopolitical Tensions

12. Sept. 2026, 23:21 UTC

U.S. Export Prices Expected to Rise in August Amid Positive Economic Sentiment and Fed Rate Speculations

12. Sept. 2026, 23:21 UTC

U.S. Retail Sales Expected to Rise 0.9% in August Amid Cautious Market Sentiment Following July's Decline

12. Sept. 2026, 23:11 UTC

Canada's housing starts data release on September 16, 2026, expected at 235,000 units amid cautious market sentiment following July’s shortfall.

12. Sept. 2026, 23:01 UTC

NY Empire State Manufacturing Index Set for Release Amid Mixed Economic Sentiment and Inflation Concerns on September 15, 2026.

12. Sept. 2026, 23:01 UTC

Market Awaits ECB President Lagarde's Speech Amid Speculation of Future Rate Hikes and Leadership Changes Following Recent Interest Rate Increase.

12. Sept. 2026, 22:51 UTC

Brazil's Central Bank Set to Announce SELIC Rate Decision Amid Global Monetary Tightening and Rising Inflation Concerns on September 14, 2026.

12. Sept. 2026, 22:51 UTC

Japan's Core Inflation Rate Expected to Rise to 1.8% Amid Global Economic Pressures Ahead of Bank of Japan Meeting

12. Sept. 2026, 22:51 UTC

Japan's Upcoming Inflation Rate Report Expected to Reflect Mixed Signals Amid Rising Energy Costs and Producer Price Fluctuations

12. Sept. 2026, 22:41 UTC

Canada's August Inflation Rate Release on September 14 Expected to Show Continued Pressure Amid Geopolitical Tensions and Rising Oil Prices.

12. Sept. 2026, 22:41 UTC

Canada's Core Inflation Rate Expected to Rise to 2.4% Amid U.S. Economic Indicators and Speculation of Fed Interest Rate Hikes

12. Sept. 2026, 22:41 UTC

Rising U.S. 30-Year Mortgage Rates Exceed 7%, Threatening Housing Demand and Economic Growth Ahead of Key Central Bank Meetings

12. Sept. 2026, 22:41 UTC

Canada's Inflation Rate Expected to Hold Steady at 0.0% Amid Global Economic Concerns Ahead of September Release

12. Sept. 2026, 22:41 UTC

Macro News

The DAX 30 Index is lower in after-market trading, pressured by rising crude oil prices and concerns over Treasury yields and interest rate hikes.

12. Sept. 2026, 22:31 UTC

Japan's trade deficit forecasted at -1052.6 billion yen for August 2026 amid rising import costs and negative market sentiment.

12. Sept. 2026, 22:31 UTC

Japan's August Exports YoY Data Set for Release Amidst Cautious Market Sentiment and Economic Concerns

12. Sept. 2026, 22:31 UTC

Japan's Machinery Orders Expected to Decline Amid Market Volatility and Inflation Concerns

12. Sept. 2026, 22:31 UTC

Brazil's Retail Sales Report on September 15 Expected to Show Month-on-Month Growth Amid Inflationary Pressures

12. Sept. 2026, 22:11 UTC

Bank of England Expected to Maintain Interest Rate at 0.667% Amid Global Economic Caution and Inflation Concerns

12. Sept. 2026, 21:01 UTC

Oil (Brent) is trading lower during after-market hours, continuing a decline since Friday's close. The market shows weakness despite remaining above its 20-day moving average.

12. Sept. 2026, 21:01 UTC

India's August Inflation Rate Release on September 14 Expected at 4.8%, Amid Rising Global Energy Costs and Geopolitical Tensions

12. Sept. 2026, 21:01 UTC

EUR/PLN traded roughly flat during after-market hours, remaining around the middle of its one-month range with no specific news identified.

12. Sept. 2026, 20:51 UTC

API Crude Oil Stock Change Data Release on September 15 Expected to Show Continued Inventory Decline Amid Easing Geopolitical Tensions and Inflation Concerns.

Peer-Vergleich

Kursveränderung

Corvus Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

128.51% Vorteil

12-Monats-Prognose

Durchschnitt 29.5 USD 128.51%

Hoch 33 USD

Tief 27 USD

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Corvus Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

4 ratings

Buy

Halten

Sell

Basierend auf 4 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Corvus Pharmaceuticals Inc – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.